Hanna Rosenbaum Selected Research

taliglucerase alfa

1/2019	Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
1/2016	Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
1/2016	Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
12/2014	A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
11/2011	Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hanna Rosenbaum Research Topics

Disease

23	Gaucher Disease (Gaucher's Disease) 01/2020 - 01/2002
3	Anemia 01/2019 - 01/2002
3	Cytopenia 02/2015 - 11/2013
2	Rare Diseases (Rare Disease) 01/2020 - 01/2011
2	Thrombocytopenia (Thrombopenia) 01/2019 - 10/2014
2	Pulmonary Hypertension 02/2015 - 11/2013
2	Parkinson Disease (Parkinson's Disease) 11/2005 - 11/2004
1	Splenomegaly 01/2019
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2016
1	Body Weight (Weight, Body) 12/2014
1	Hypersensitivity (Allergy) 11/2011
1	Hemolysis 04/2010
1	Multiple Myeloma 09/2007
1	Parkinsonian Disorders (Parkinsonism) 11/2004
1	Cholelithiasis 01/2002
1	Gallstones (Gallstone) 01/2002

Drug/Important Bio-Agent (IBA)

9	Glucosylceramidase (Glucocerebrosidase)IBA 08/2015 - 01/2002
7	eliglustatIBA 01/2019 - 08/2010
5	taliglucerase alfaIBA 01/2019 - 11/2011
5	Glucosylceramides (Glucocerebrosides)IBA 08/2015 - 01/2002
4	EnzymesIBA 08/2015 - 01/2002
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2016
2	imiglucerase FDA Link 01/2016 - 12/2014
1	Biosimilar PharmaceuticalsIBA 01/2020
1	HDL LipoproteinsIBA 01/2018
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2018
1	oxidized low density lipoproteinIBA 01/2018
1	Azacitidine (5 Azacytidine)FDA Link 10/2016
1	Lenalidomide (CC 5013)FDA Link 10/2016
1	GlucosidasesIBA 12/2014
1	Blood Coagulation Factors (Coagulation Factor)IBA 10/2014
1	Glucose (Dextrose)FDA LinkGeneric 10/2014
1	Hemostatics (Antihemorrhagics)IBA 10/2014
1	CeramidesIBA 10/2014
1	Immunoglobulin G (IgG)IBA 11/2011
1	Pharmaceutical PreparationsIBA 11/2011
1	Hemoglobins (Hemoglobin)IBA 11/2010
1	ceramide glucosyltransferaseIBA 08/2010
1	AntioxidantsIBA 04/2010
1	fermented papaya preparationIBA 04/2010
1	Immunoglobulins (Immunoglobulin)IBA 09/2007

Therapy/Procedure

9	Enzyme Replacement Therapy 01/2019 - 11/2010
7	Therapeutics 01/2019 - 08/2010
1	Splenectomy 01/2002
1	Cholecystectomy 01/2002